Clinical Monograph: CoQ10 (Ubiquinol) on Mitochondrial ATP Synthesis & Cardiovascular Endpoints
Clinical meta-analyses confirm that Coenzyme Q10 (specifically reduced Ubiquinol) significantly improves left ventricular ejection fraction (LVEF), attenuates statin-associated muscle symptoms (SAMS), and restores cellular redox equilibrium.
Key Clinical Takeaways & Systematic Review Summary
Clinical meta-analyses confirm that Coenzyme Q10 (specifically reduced Ubiquinol) significantly improves left ventricular ejection fraction (LVEF), attenuates statin-associated muscle symptoms (SAMS), and restores cellular redox equilibrium.
- Evidence Classification: Rigorously graded under standardized Cochrane & GRADE systematic review protocols.
- Literature Benchmark Dosage: 200 mg – 300 mg daily.
- Pharmacokinetic Timing: Must be taken with dietary fats for lipid-soluble micellar absorption..
- Active Primary PubMed Reference: PMID 25282031 (JACC: Heart Failure).
Participate in Paid Clinical Research Studies ($750–$2,200 Stipends)
Accredited medical research centers are actively enrolling qualified participants for metabolic health, incretin therapy, and longevity studies. All physician evaluations, lab panels, and investigational compounds are provided at zero cost.
Check Clinical Trial Match Eligibility →Interactive Clinical Calculators & Drug Interaction Checkers
Calculate individualized body-weight dosages, check contraindications against prescription medications, and analyze 24-hour synergy schedules using our free interactive tool suite: